Laatste resultaten 23 jul 2026
Roche Holding Ltd ADR
I · AI-analyse
In het kort
Roche develops and sells prescription medicines for serious diseases—primarily cancer, autoimmune conditions, neurological disorders, and infectious diseases—while also manufacturing diagnostic instruments and laboratory tests that help doctors detect illnesses early [Yahoo Finance]. The company operates two main divisions: pharmaceuticals (drugs) and diagnostics (medical tests and equipment), serving hospitals, clinics, and laboratories across six continents.
Roche Holding is a Swiss pharmaceutical and diagnostics giant with over 103.000 employees, generating $63,4B in annual revenue from medicines treating cancer, autoimmune diseases, and infectious conditions, plus diagnostic tests for diseases like COVID-19 and hepatitis [Yahoo Finance]. The company recently won FDA approval to expand its blockbuster cancer drug Tecentriq into bladder cancer and is advancing a promising experimental breast cancer treatment called giredestrant [Yahoo Finance]. Financially, Roche stands on rock-solid footing with a health score of 8,9/10, strong free cash flow of $13,1B, and minimal net debt at just 0,6x EBITDA [Yahoo Finance] [Sentinellis calculation].
Roche is financially robust with excellent profitability, minimal debt, and very strong cash generation.
Sentinellis-score
8,9/10
Financieel gezond
Marktkapitalisatie
$334,0B
Omzet (12 maanden)
CHF 63,4B
Uitleg
Hoe wij deze cijfers lezen
Begrijpelijke gidsen · geen account nodig
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LezenPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LezenAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LezenII · Recent nieuws
Wat de koers bewoog
6 berichten · gesorteerd op relevantie
- Macro2026-05-20
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
Zacks
- Macro2026-05-19
Idiopathic Pulmonary Fibrosis Market Dynamics, Opportunity Analysis and Forecast Report 2026-2035: Therapeutic Landscape is Anchored by Two Key Products - Esbriet (Pirfenidone), and Ofev
Yahoo Finance
- Macro2026-05-19
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
Yahoo Finance
- Macro2026-05-19
Polymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer
Yahoo Finance
- Macro2026-05-18
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer
Yahoo Finance
- Macro2026-05-18
Middle East and Africa Wearable Injectors Market Trends and Forecast Report 2026-2035 Featuring Amgen, BD, Biocon, Gerresheimer, Insulet, J&J, Medtronic, Roche, West Pharmaceutical, Ypsomed
Yahoo Finance
Premium · gratis met elk account
Revenue growth of just 1,5% year-over-year signals Roche faces challenges expanding sales, possibly due to patent expirations on older blockbuster drugs or intensifying competition in key therapeutic areas [Yahoo Finance].
Risico's
4
Kansen
5
Waarschuwingssignalen
2
Leiding
6
Nog 10 bevindingen in het volledige rapport — gratis met elk account.
Ontgrendel de volledige analyse van Roche Holding Ltd ADR
Maak een gratis account voor het volledige AI-rapport met bronvermelding in de tekst.
- 4 risico's, 5 kansen en 2 waarschuwingssignalen — elk met zijn bron
- Meer dan 100 financiële cijfers met grafieken en vergelijkingen
- Volledige nieuwssamenvattingen met bronlinks
- Directie en beloning
III · Vergelijkbare bedrijven
Misschien ook interessant
Zelfde sector · Gezondheidszorg — of vergelijkbare financiële gezondheid
Op je volglijst zetten?